What if You Could ‘Reveal’ Autism and/or ADHD via an AI Neurological Diagnostic Solution?

ARC, Sheba’s global healthcare transformation engine and innovation arm announced a collaboration with Revealense, creators of a neurological-AI engine for analyzing behavioral DNA in video footage, to establish a joint venture focused on delivering an advanced neurological diagnostic solution. The joint solution will deliver precise, clinically validated diagnoses across a wide range of neurological, cognitive, and developmental conditions via a standard webcam in the comfort of a patient’s home.

The collaboration between ARC and Revealense signals a new era in neurological diagnostics—digital, personalized, science-driven, and powered by a neurological-AI engine. This innovative model has the potential to redefine diagnostic standards, reduce time to treatment, and deliver more accurate, efficient, and individualized care across a wide range of neurological and developmental conditions.

The first diagnostic protocols, led by Dr. Omer Bar Yosef, Director of the Child Development Center at Sheba Medical Center, will focus on autism, ADHD, and related conditions. Beyond dramatically reducing the time needed for diagnosis, the venture also aims to enable earlier detection of syndromes, potentially allowing for initial assessments of autism and other conditions as early as 6 to 12 months of age.

The new integrated clinical and technological solution will allow diagnostic assessment to be conducted at home via standard webcam, creating a more accessible and convenient process and enabling more accurate data collection by allowing subjects to remain in their natural environment. Unlike conventional tools, the behavioral analysis platform will assess an individual’s condition, factor in environmental influences, monitor changes over time, and recommend personalized, treatment-supporting care plans tailored to each user. Additionally, the system will determine the subject’s baseline condition prior to the assessment process, addressing several shortcomings in current neurological diagnostics.

Dov Donin, Founder and CEO of Revealense, said, “This strategic collaboration between Revealense and Sheba’s ARC innovation center represents a profound shift in how we understand, diagnose, and treat neurological disorders. With computational models, deep psychophysiological measurements, and real-time monitoring, we are at the forefront of a clinical revolution. It’s not just a new technology—it’s a paradigm shift that can improve and even save lives, while elevating the entire diagnostics landscape. We plan to accelerate development and regulatory processes in the coming months, with the goal of reaching the market in early 2026.”

Avner Halperin, CEO Sheba Impact at ARC, Sheba’s commercialization arm added, “The collaboration with Revealense exemplifies Sheba and ARC’s unique innovation model—which brings together clinicians on the ground, technological excellence, and robust infrastructure to establish entrepreneurial initiatives. This partnership will enable a faster neurological diagnostic process with increased accuracy and reliability, while improving accessibility by moving from the clinic to home.”